Estrogen receptor B (ERB) is the predominant ER in the colorectal epithelium. Compared with normal colon tissue, ERB expression is reduced in colorectal cancer. Our hypothesis is that ERB inhibits proliferation of colon cancer cells. Hence, the aim of this study has been to investigate the molecular function of ERB in colon cancer cells, focusing on cell cycle regulation. SW480 colon cancer cells have been lentivirus transduced with ERB expression construct with or without mutated DNA-binding domain or an empty control vector. Expression of ERB resulted in inhibition of proliferation and G 1 phase cell cycle arrest and this effect was dependent on a functional DNA-binding region. c-Myc is overexpressed in an overwhelming majority of colorectal tumors. By Western blot and real-time PCR, we found c-Myc to be down-regulated in the ERB-expressing cells. Furthermore, the c-Myc target gene p21 (Waf1/Cip1) was induced and Cdc25A was reduced by ERB at the transcriptional level. The second cdk2-inhibitor, p27 Kip1 , was induced by ERB, but this regulation occurred at the posttranscriptional level, probably through ERB-mediated repression of the F-box protein p45 Skp2 . Expression of the ERB-variant with mutated DNA binding domain resulted in completely different cell cycle gene regulation. We performed in vivo studies with SW480 cells F ERB transplanted into severe combined immunodeficient/beige mice; after three weeks of ERB-expression, a 70% reduction of tumor volume was seen. Our results show that ERB inhibits proliferation as well as colon cancer xenograft growth, probably as a consequence of ERB-mediated inhibition of cell-cycle pathways. Furthermore, this ERB-mediated cell cycle repression is dependent on functional ERE binding. [Cancer Res 2009;69(15):6100-6] 
Introduction
The majority of sporadic colon cancers are believed to develop through a gradual process of mutations including inactivation of the APC gene. This molecular process corresponds to development of polyps and subsequently adenomas of the colonic epithelium (1) . Randomized, placebo-controlled clinical trials, designed to investigate the risk of hormone replacement therapy, indicates that progestin-estrogen hormone replacement therapy reduces the incidence of colorectal carcinoma (2, 3) . Interestingly, there are also indications that use of oral contraceptives is associated with a lower incidence of colorectal cancer (4) . Several possible explanations have been presented. Estrogens affect the metabolism of bile acids, reduce insulin-like growth factor (IGF-I) levels in the bloodstream, and have direct effects on the colonic mucosa (5-7). In the human colonic epithelium, estrogen receptor h (ERh) is the predominant ER (8, 9) . The ERs mediate their effects by binding to estrogen response elements (ERE) in gene promoters but also indirectly through activator protein (AP-1) and SP-1 sites (10) .
A striking reduction of ERh expression occurs in colon cancer compared with normal colonic epithelium, and furthermore, the level of ERh seems to be inversely correlated to differentiation grade and Dukes score (11, 12) . This raises the question whether ERs in the colonic epithelium could have a function as tumor suppressors in early colonic neoplasms (13) . To investigate the function of ERh in colon cancer, we have generated ERh-expressing SW480 colon cancer cells by lentiviral transduction of an ERh expression cassette. Also, we have used an ERh with mutated DNA-binding domain (DBD-mutation) to investigate if effects of ERh on gene transcription are dependent on ERE-binding or not. The transformation of normal colonic epithelial cells to colon cancer involves a sequential alteration in gene expression profile, involving induced expression of several cell cycle genes (1, 14) . The cell cycle is a central pathway in carcinogenesis and development of a malignant disease. c-Myc is overexpressed in a majority of colon cancers and is believed to be an important factor in the transformation process (15, 16) . c-Myc is one of the first genes to be expressed in the cell cycle, in turn regulating the expression of secondary cell cycle genes. However, there are other more or less c-Myc-independent cell cycle factors of importance in colon cancer growth and metastasis. Recently, several studies have shown a correlation of decreased p27
Kip1 protein levels (p27) with poor overall survival compared with patients with high levels of p27 in their tumor (17) . The main regulator of p27 protein level is the F-box protein p45
Skp2 , which targets the protein for degradation through the proteasome complex. In addition, a correlation of increasing p45
Skp2 levels (p45) with increased number of lymph node metastases has been found (18) . Interestingly, both c-Myc and p27 are regulated by ERa in breast cancer cells and we have earlier shown that ERh induces p27 in breast cancer cells (19) . Consequently, we are now investigating the effects of ERh on the c-Myc and p27 pathways in colon cancer cells.
(SW480-ERh), (HCT-116-ERh), and (HT29-ERh) or with empty vector as control (SW480-Control), (HCT-116-control), and (HT29-control). SW480 cells were also transduced with ERh-construct with mutated DBD-domain (SW480-ERh-DBDmut) to investigate the importance of ERE binding in ERh signaling. Both ERh constructs were expressed at similar levels in SW480 cells. The plasmid pcDNA3-FLAG ERh was used as a template for TOPO cloning into pLenti6/V5-D-TOPO according to the manufacturer's instructions (Invitrogen). The pLenti6/V5-D-FLAG ERh DBDmut was constructed from pLenti6/V5-D-FLAG ERh using Quick-Change (Stratagene) according to the manufacturer's instructions. Forward oligo ATCACTATGGAG TCTGGTCGTTG CA GCATGTAAGGCCTTTTTTAAAA GA changing amino acid residues E167 and G168, glutamic acid and glycine, respectively, to alanine. Lentivirus was then produced with the ViraPower Lentivirus expression system and infection was performed as described earlier (20) . The lentivirus-treated cells were then incubated with 5 Ag/mL Blasticidine, resulting in death of nontransduced cells. The corresponding ERa DBD mutant has been characterized earlier. The ERh DBD mutant was further characterized in an ERE luciferase activation assay where wild-type ERh, but not the DBD-mutated ERh, activated ERE-luciferase transcription. The lentivirus transduction was made in independent triplicates for each construct (ERh, ERh-DBDmut, and control). The cells were cultured in RPMI 1640 (Life Technologies/Invitrogen) with 5% fetal bovine serum (FBS). Medium was changed to phenol red-free RPMI 1640 with 5% dextran/ charcoal-treated FBS (stripped medium) 24 h before start of experiment. The cells were then incubated with 10 nmol/L E 2 or ethanol as control for 24 h in stripped medium.
Proliferation assay. To investigate the ERh-mediated effects on cellular proliferation, 2 Â 10 5 SW480, HCT-116, and HT29 cells, respectively, were virally transduced with either ERh-construct or empty control vector and were plated onto 6-cm cell culture dishes in RPMI 1640. The plating efficiency was similar in the different plates. After 72 h, the cells were counted manually with a Bürkner chamber. Experiments were performed with three different clones, each in three separate dishes.
Flow cytometry. Flow cytometry was performed to observe different cell cycle distributions of the SW480 clones. Cells were treated with mevinolin at 40 Amol/L (Sigma) for 36 h before the start of the experiment to ensure cell synchronization. Cells were then released into media containing 5% serum, harvested at 0, 16, 24, and 36 h by trypsinization and fixed in 70% cold ethanol for 30 min on ice. The fixed cells were washed in PBS and stained with 50 Ag/mL propidium iodide (Sigma) supplemented with RNase A (50 Ag/mL; Sigma) for 30 min at 37jC. Fluorescence-activated cell sorting (FACS) was performed using a FACS Calibur flow cytometer (Becton Dickinson). Cell cycle analysis was performed using CELLQuest program (Becton Dickinson).
Western immunoblotting and antibodies. SDS-PAGE was performed as described earlier (21) , with the primary intention to investigate regulation of G 1 -phase cell-cycle factors. The following primary antibodies were used for incubations: against ERh(Abcam), h-actin (Sigma), c-Myc sc-764, Cyclin A sc-751, Cyclin E sc-247, p27
Kip1 sc-1641, p21 (Waf1/Cip1) sc-19, p45
Skp2 sc-7164, p15 sc-612, p16 sc-468, and p14 ARF sc-8613 (all from Santa Cruz Biotechnology); pRb-antibody sampler kit (Cell Signaling); and Cdc25A Ab-3 ( from NeoMarkers).
RNA-extraction and real-time PCR. RNA extraction with TRIzol (Invitrogen) was done according to standard protocol. RNA was purified with Qiagen RNeasy spin columns (Qiagen) with on-column DNase I digestion ( for subsequent Microarrray-experiment). cDNA was synthesized with NBS First Strand System (Nordic Bioservice).
Real-time PCR was performed with NBS Probe or NBS SYBR Mastermixes (Nordic Bioservice). Primer/probe sequences will be provided on request. The real-time PCR reactions were performed in an ABI PRISM 7500 (Applied Biosystems) under the following conditions: 10 min hot start at 95jC, followed by 15 s at 95jC, and 60jC for 50 s in totally 40 cycles. The optimum concentration of primers was determined in preliminary experiments and all SYBR-Green primer pairs were checked with melting curve analysis.
Immunohistochemistry. To examine the number of proliferating cells in F ERh-expressing tumor xenografts, immunohistochemistry with a Ki-67 antibody was performed. Antigen retrieval was done by microwave boiling in 0.01 mol/L citric acid (pH 6.0) for 120 s and then slides were left undisturbed for 20 min. Endogenous peroxidase activity was blocked by incubating sections shaking in 3% hydrogen peroxide in methanol for 10 min and then blocked in 2% Bovine Serum Albumin (BSA) and 0.1% NP40 for 1 h at room temperature. Primary antibody Ki-67 (DakoCytomation) was diluted 1:100 in 2% BSA and 0.1% NP40 and incubated overnight at 4jC. Sections were then washed consecutively in PBS, 0.1% NP40 for 3 Â 5 min, followed by incubation with a biotinylated antibody BA-9200 1:200 in 0.1% NP40 for 1 h (Vector Laboratories). After this, sections were incubated in the streptavidin-horseradish peroxidase ABC complex (Vectastain Elite; Vector Laboratories) for 1 h, stained in 3,3 ¶-diaminobenzidine and counterstained with Mayer hematoxylin (Sigma) before dehydration through ethanol, and mounted in Pertex (Histolab). The number of Ki-67-positive cells was counted on two independent fields per slide with Â20 objective. The average number of positive cells and SD were calculated for each group.
Experimental animals and xenograft model. SW480 colon cancer cells F ERh expression were implanted into immunodeficient mice to investigate tumor growth. SW480-ERh/control cells (5 Â 10 6 ) were diluted in 200 AL normal medium + 200 AL Matrigel (BD Biosciences) and injected into the abdominal fat close to the mammary tissue of 9-to 12-wk-old pathogenfree severe combined immunodeficient (SCID)/beige mice (Taconic) on day 0. E 2 pellets, 0.72 mg/pellet (IRA), were inserted s.c. into the neck with a pellet trochar (IRA). After 14 d, the mice were sacrificed and the tumor weight was measured. All tumors were fixed in 4% paraformaldehyde and stored in 75% ethanol. After this, tissues were paraffin embedded and subsequently sliced into 4.5-Am sections according to standard protocol.
Statistics. Values are expressed as means with 95% confidence intervals. For real-time PCR analysis, unpaired two-tailed t test was used to compare differences between two parallel treatment groups of identical origin. Mann-Whitney U test was used to test differences between two groups of nonparametric data. Significance is presented as P value of <0.05 (*), <0.01 (**), and <0.001 (***); nonsignificant differences are presented as NS.
Results
Colon cancer epithelial cells do not contain ERa but varying amounts of ERh. The SW480 as well as most other colon cancer cell lines grown in vitro contain very low levels of ERh. To confirm this, we performed real-time PCR with primers/probe specific for ERa and ERh mRNA, respectively. As expected, we found no ERa and very low levels of ERh expression in SW480 cells (data not shown). To be able to study the effect of ERh in these cells, we used lentiviral transduction of an ERh expression cassette. In Fig. 1 , we show the expression of ERh mRNA and protein in these cells (A). The level of ERh was not affected by E 2 treatment. Expression of exogenous ERh decreased the proliferation compared with SW480 cells transduced with empty expression cassette (SW480-control) as shown in Fig. 1B . As a comparison, two other colon cancer cell lines, HCT-116 and HT29, were transduced with an ERh expression cassette (HCT-116-ERh and HT29-ERh). The proliferation of HCT-116 cells was reduced in presence of ERh expression. However, the proliferation of HT29 cells was not reduced to a significant level (Fig. 1C) . We then performed flow cytometry to investigate the cell cycle distributions of the SW480-clones. Thirty-six hours after start of experiment, 75% of SW480-ERh cells were distributed in the G 1 phase, whereas 52% of SW480-control cells were in the G 1 phase (Fig. 1D ) . Mutation of the DNA-binding domain of ERh (SW480-ERh-DBDmut) resulted in a nearly complete removal of the ERh-mediated G 1 arrest, resulting in 58% of the cells distributed in the G 1 phase. In agreement with this, expression of ERh-DBDmut did not reduce the proliferation of SW480 cells as measured with proliferation assay (data not shown).
We went on to investigate the regulation of the most important genes governing proliferation in the G 1 -S phase. Western blot was performed and the results are shown in Fig. 2A . The immediate early gene c-Myc was down-regulated by ERh expression and, as expected, the c-Myc target gene Cdc25A was also repressed by ERh. p14 ARF , a tumor suppressor involved in both cell-cycle arrest and apoptosis, was induced by ERh. p14 ARF functions by downregulating MDM2 and, in this way, stabilizing p53-protein. As a consequence, we found p53 to be stronglyinduced by ERh.
The cdk4/6-inhibitors p15 and p16 were not affected by ERh at the protein level.Cyclin E and A, important in the late stage of the G 1 phase, were not affected significantly, whereas Cyclin D1 was up-regulated at the protein level. The cdk2-inhibitors p21 (Waf1/Cip1) (p21) and p27 showed strong induction following ERh expression and the expression of p45, which is the regulator of p27-degradation, was down-regulated by ERh. Forced expression of Retinoblastoma protein (pRb) efficiently blocks cell cycle transition and pRb is often mutated or inactivated in tumorigenesis resulting in free E2F1 (22) . Interestingly, we found that total amount of pRb was increased in the ERh-expressing cells compared with the control. Phosphorylation status of pRb was changed as well, resulting in increased phospho-Ser780 and decreased phosphoSer795 following ERh expression.
However, SW480 cells expressing ERh-DBDmut showed a completely different protein expression pattern (Fig. 2B) . The DBD-domain is responsible for binding of ERh to EREs. Therefore, the DBD-mutant is crucial to investigate potential ERE-dependent activation/inactivation by ERh. Cdc25A was induced by ERhDBDmut, whereas p21 and p27 were not induced to the same extent as by wild-type ERh. Furthermore, c-Myc was not repressed to as large extent as in the SW480-ERh cells.
In HT29 cells (Fig. 2C) , c-Myc, p21, p27, and p53 were all regulated by ERh expression in a similar fashion as in SW480 cells. However, ERh expression in HCT-116 cells caused a reduction of p53 and p21 levels but also of c-Myc, whereas p27 was not significantly changed.
To investigate the regulation of these proteins at the mRNA level, we performed real-time PCR (Fig. 3) on SW480-ERh, SW480-control, or SW480-ERh-DBDmut. We found that c-Myc mRNA was down-regulated >70% by ERh expression independently of E 2 , and this effect was dependent on a functional DBD (Fig. 3A) . Cdc25A mRNA expression was also reduced by ERh, but not by the ERhDBDmut (Fig. 3C ). There were no significant differences in mRNA expression of Cyclin E or Cyclin A by ERh (Fig. 3A) , whereas Cyclin A expression was reduced by ERh-DBDmut. Cyclin D1 mRNA expression was up-regulated in SW480-ERh in a DBD-dependent fashion. p21-mRNA was up-regulated in SW480-ERh independent of the DBD, indicating that the regulation of p21 by ERh occurs independently of ERE-binding. p27 mRNA was not regulated by ERh (Fig. 3B) but was induced by ERh-DBDmut; however, this induction was nonsignificant (P = 0.32, bars 2 versus 6). There was a strong reduction of p45-mRNA in SW480-ERh cells dependent on a functional DBD. As expected, pRb was not regulated at the mRNAlevel by ERh but was strongly repressed by the ERh-DBDmut, an effect which we cannot explain at present (Fig. 3C) . p14 ARF and p53 were not affected significantly at the mRNA-level (data not shown).
To obtain a more complete view of the antitumorigenic role of ERh, we investigated how ERh expression affected growth of SW480-xenografts (Fig. 4) . SW480-control or SW480-ERh cells All experiments above were repeated twice with identical results. Statistics presented as P < 0.01 (**), P < 0.001 (***); NS, nonsignificant differences.
were transplanted into the right flank of SCID/beige mice ( Fig. 4A) . At end point, the average weight of SW480-control xenografts was 704 mg, whereas average weight of SW480-ERh xenografts was 245 mg, a reduction of tumor weight by 65% following ERh expression (Fig. 4A and B) . Immunohistochemistry with a Ki67-specific antibody was performed. The xenografts in the mice injected with ERh-expressing cells showed a significant downregulation of the number of Ki67-positive cells (Fig. 4C and D) . A TUNEL assay was performed on the xenografts to detect apoptosis, but there was no significant difference in apoptosis between SW480-ERh and SW480-control xenografts (data not shown).
Moreover, microarray studies were performed to investigate genome-wide transcriptional effects as a result of long-term expression (3 weeks) of ERh in SW480 cells. ERh expression resulted in dramatic changes of the transcriptome; 623 differentially regulated transcripts were detected and the effect was mainly repressive (Supplementary Data). (24). This finding might reflect alternative signaling pathways in proliferation of HT29 cells. Interestingly, this type of mechanism is well known in breast cancer cells, where ERa-cancers are frequently dependent on tyrosine-kinase signaling to proliferate (25) . Moreover, the total ERh level in the transduced cells was lower in HT-29 cells compared with HCT-116 and SW480.
We performed both real-time PCR analysis of rate-limiting cell cycle factors in the G 1 phase as well as microarray analysis for the overall effects by ERh expression (Supplementary Data). We found several proliferation-regulating genes to be transcriptionally inhibited by ERh. c-Myc is an important immediate early gene, and an activator of numerous G 1 -S-phase genes. Expression of c-Myc has been shown to counteract a dnTCF-4 expressed in the colon cancer cell line HT29 with respect to effects on proliferation. This points toward c-Myc as a central factor in colon cancer growth, neutralizing the effect of the APC tumor suppressor (16) . We found that ERh was a strong inhibitor of c-Myc expression at both mRNA and protein levels, which could be an important step in the repression of proliferation by ERh. c-Myc expression affects the transcription of many proliferation-associated genes and Cdc25A is one of the most well-known targets (26) . We found Cdc25A to be repressed at mRNA and protein-levels by ERh, most likely dependent on c-Myc repression. In SW480-ERh-DBDmut, c-Myc was induced at mRNA level but not as strongly regulated at protein level; therefore, it is likely that ERh-mediated repression occurs through ERE binding.
In response to c-Myc overexpression, normal cells undergo p53-dependent apoptosis and one pathway is through induction of p14 ARF (27) . Interestingly, p14 ARF protein but not mRNA was induced in response to ERh, despite its strong inhibition of c-Myc. This indicates that ERh may induce p14 ARF through an alternative pathway. It is known that p14 ARF is regulated through proteasomal degradation (28) . Accordingly, it is possible that ERh regulates p53 by affecting p14 ARF degradation. Induction of p53 by ERh through p14 ARF could be a novel pathway important for ERh-mediated apoptosis in premalignant lesions with wild-type p53.
p21 is an important downstream effector of p53-signaling in parallel to its proapoptotic effects and p21 was found to be up-regulated in the ERh-expressing cells. SW480 cells contain a mutated form of p53, presumably without proapoptotic potential but with some transcriptional activity such as the ability to induce p21 (29) . In line with this, we could not find increased apoptosis in the ERh-expressing tumor xenografts, but a strong induction of p21-protein in vitro.
We also analyzed the ERh-mediated regulation of cell cycle genes in two other colon cancer cell lines: HCT-116 and HT29. Cell cycle regulation at protein level by ERh was very similar in HT29 cells compared with SW480. Interestingly, in HCT-116 cells, which contain a nonmutated, wild-type p53, this protein was strongly reduced by ERh, for unknown reasons. Furthermore, the p53 target gene p21 was reduced. Most interestingly, the expression of c-Myc was reduced in both cell lines, further strengthening the role of c-Myc as a central ERh-regulated cell cycle gene.
The other major cell cycle pathway regulated by ERh was the p45-p27 pathway. p27-protein but not p27-mRNA was induced by ERh expression. Therefore, we investigated whether p45, governing p27 degradation, was affected by ERh. We found that p45 was strongly reduced at protein and mRNA-levels. We believe that the combined c-Myc reduction and p27/p21 induction efficiently inhibits cell cycle progression. We have earlier studied the effects of ERh in breast cancer cells (19, 30) where c-Myc was reduced and p21 and p27 were induced. Remarkably, Cyclin D1 was induced by ERh in colon cancer cells and this was seen in breast cancer cells as well, but even under these conditions, proliferation was inhibited. pRb is an important tumor suppressor, often mutated and inactivated in human malignancies. We found that total pRb level was up-regulated by ERh expression. Phosphorylation status of pRb was changed as well with increased phospho-Ser780, which requires Cyclin D-cdk4/6 activity (31) and decreased phospho-Ser795 following ERh expression. This indicates that the increase in Cyclin D1-level causes an activation of the Cyclin D1-cdk4/6-complexes, and a partial phosphorylation of pRB. Still, the antiproliferative and antitumorigenic effects of ERh expression are strong, which means that ERh probably has its major effect on a parallel or downstream target. It is believed that complete inactivation of pRb and dissociation of E2F1 requires sequential phosphorylation of pRb by the Cyclin E/A-cdk2 complexes as well (32) . Therefore, we suggest that the combined action of increased cdk2-inhibitor levels (p21 and p27), decreased Cdc25A-level and, not least, increased pRB-levels results in strong inhibition of proliferation by inactivation of the Cyclin E/A-cdk2 complexes.
We have used an ERh construct with mutated DNA-binding domain (ERh-DBDmut) to investigate ERh effects in absence of functional, classic ERE binding. Several genes are regulated by ERa and ERh through nonclassic binding sites such as AP-1 and SP-1, independently of a functional DBD region. Therefore, the ERh-DBDmut does not work as a negative control for ERh signaling. It is likely that in genes where the ERh effects are completely dependent on ERE binding, the effects can be reversed with the ERh-DBDmutant. On the other hand, when the ERh effects are mediated through other promoter elements, the expression of the ERh-DBDmut can result in both induction and repression of transcription. Based on the findings in this article, we conclude that the antiproliferative effect of ERh in colon cancer cells is dependent on ERE binding and, hence, a functional DBD region. Most interestingly, to our knowledge, this is the first study to indicate a ligand-independent, ERE-mediated regulation by ERh. However, we cannot rule out the possibility that the E 2 independence is a result of ERh overexpression. But today, no colon cancer cell lines with endogenous ERh are available.
Our in vivo xenograft experiments indicate that ERh efficiently blocks tumor growth. However, because all xenografts grew in presence of E 2 , we do not know whether estrogens further strengthen the antiproliferative function of ERh. This should be investigated in future studies. Loss of ERh is seen in the progression of several types of malignancies, e.g., in breast, ovarian (33) , and colon cancer. Konstantinopoulos and colleagues (11) , among many authors, showed that reduction in ERh expression Figure 4 . SCID/beige mice transplanted with SW480 cells expressing ERh (SW480-ERb ; n = 6) or with empty vector (SW480-control ; n = 6). The cells were mixed with Matrigel and implanted into mammary fat pad. All mice were subsequently implanted with slow-release E 2 pellet. After 3 wk, mice were sacrificed and photographed. A, SW480-control and SW480-ERh cell-transplanted mice, with arrows pointing at injection site and picture of the removed xenografts at end point. Scale in centimeters. B, tumor weight at end point. C, number of Ki67-positive cells in xenograft slides per visual field (Â20 objective) identified by immunohistochemistry. Bar 1, SW480-control xenografts; bar 2, SW480-ERh xenografts. Number of positive cells was counted in two independent areas on each xenograft slide. Columns , average number; bars , SD. ***, P < 0.001. D, representative pictures of Ki67-immunohistochemically stained slides from SW480-control xenografts and SW480-ERh xenografts.
was correlated with the degree of tumor differentiation, poorly differentiated tumors exhibiting a larger loss of ERh compared with moderately or well-differentiated tumors. It is interesting to note that reduced p27 and increased p45 are correlated to higher aggressiveness in many types of cancer (34, 35) in line with a regulation of these factors by ERh.
In conclusion, ERh inhibits proliferation and tumor growth of colon cancer cells by regulating G 1 -phase cell cycle genes. Moreover, this regulation is dependent on a functional DBDdomain of ERh.
Disclosure of Potential Conflicts of Interest
J-A. Gustafsson: commercial research grant, consultant, and ownership interest, KaroBio AB. The other authors disclosed no potential conflicts of interest.
